nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—Diuresis—Cisplatin—peripheral nervous system neoplasm	0.0179	0.0215	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Cisplatin—peripheral nervous system neoplasm	0.0174	0.0209	CcSEcCtD
Dihydroxyaluminium—VDAC3—trigeminal ganglion—peripheral nervous system neoplasm	0.017	0.147	CbGeAlD
Dihydroxyaluminium—VDAC1—trigeminal ganglion—peripheral nervous system neoplasm	0.0162	0.139	CbGeAlD
Dihydroxyaluminium—VDAC3—parotid gland—peripheral nervous system neoplasm	0.0161	0.138	CbGeAlD
Dihydroxyaluminium—Acidosis—Isotretinoin—peripheral nervous system neoplasm	0.0155	0.0186	CcSEcCtD
Dihydroxyaluminium—Acidosis—Tretinoin—peripheral nervous system neoplasm	0.0155	0.0186	CcSEcCtD
Dihydroxyaluminium—VDAC1—parotid gland—peripheral nervous system neoplasm	0.0153	0.131	CbGeAlD
Dihydroxyaluminium—VDAC1—brainstem—peripheral nervous system neoplasm	0.0143	0.123	CbGeAlD
Dihydroxyaluminium—TNNC1—trigeminal ganglion—peripheral nervous system neoplasm	0.0139	0.119	CbGeAlD
Dihydroxyaluminium—Fluid overload—Isotretinoin—peripheral nervous system neoplasm	0.0138	0.0166	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Tretinoin—peripheral nervous system neoplasm	0.0138	0.0166	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Tretinoin—peripheral nervous system neoplasm	0.0134	0.0161	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Isotretinoin—peripheral nervous system neoplasm	0.0134	0.0161	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Topotecan—peripheral nervous system neoplasm	0.0122	0.0147	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Tretinoin—peripheral nervous system neoplasm	0.0121	0.0146	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Isotretinoin—peripheral nervous system neoplasm	0.0121	0.0146	CcSEcCtD
Dihydroxyaluminium—Acidosis—Alitretinoin—peripheral nervous system neoplasm	0.0118	0.0141	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Alitretinoin—peripheral nervous system neoplasm	0.0105	0.0126	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Cisplatin—peripheral nervous system neoplasm	0.0103	0.0123	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Alitretinoin—peripheral nervous system neoplasm	0.0101	0.0122	CcSEcCtD
Dihydroxyaluminium—Extravasation—Topotecan—peripheral nervous system neoplasm	0.00992	0.0119	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Tretinoin—peripheral nervous system neoplasm	0.00977	0.0117	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Isotretinoin—peripheral nervous system neoplasm	0.00977	0.0117	CcSEcCtD
Dihydroxyaluminium—Extravasation—Melphalan—peripheral nervous system neoplasm	0.00971	0.0117	CcSEcCtD
Dihydroxyaluminium—VDAC1—Tretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00922	0.181	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Isotretinoin—Tretinoin—peripheral nervous system neoplasm	0.00922	0.181	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Alitretinoin—Tretinoin—peripheral nervous system neoplasm	0.00922	0.181	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Alitretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00922	0.181	CbGdCrCtD
Dihydroxyaluminium—Lung disorder—Alitretinoin—peripheral nervous system neoplasm	0.00919	0.011	CcSEcCtD
Dihydroxyaluminium—VDAC2—cerebellum—peripheral nervous system neoplasm	0.00892	0.0768	CbGeAlD
Dihydroxyaluminium—Fluid overload—Cisplatin—peripheral nervous system neoplasm	0.00891	0.0107	CcSEcCtD
Dihydroxyaluminium—Extravasation—Dactinomycin—peripheral nervous system neoplasm	0.00804	0.00966	CcSEcCtD
Dihydroxyaluminium—Coma—Isotretinoin—peripheral nervous system neoplasm	0.00784	0.00942	CcSEcCtD
Dihydroxyaluminium—Coma—Tretinoin—peripheral nervous system neoplasm	0.00784	0.00942	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Tretinoin—peripheral nervous system neoplasm	0.00768	0.00922	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Isotretinoin—peripheral nervous system neoplasm	0.00768	0.00922	CcSEcCtD
Dihydroxyaluminium—VDAC3—cerebellum—peripheral nervous system neoplasm	0.00743	0.0639	CbGeAlD
Dihydroxyaluminium—Cardiovascular disorder—Alitretinoin—peripheral nervous system neoplasm	0.0074	0.00889	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Isotretinoin—peripheral nervous system neoplasm	0.00723	0.00869	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Tretinoin—peripheral nervous system neoplasm	0.00723	0.00869	CcSEcCtD
Dihydroxyaluminium—Extravasation—Vincristine—peripheral nervous system neoplasm	0.00719	0.00863	CcSEcCtD
Dihydroxyaluminium—VDAC1—cerebellum—peripheral nervous system neoplasm	0.00707	0.0608	CbGeAlD
Dihydroxyaluminium—VDAC1—Tretinoin—Alitretinoin—peripheral nervous system neoplasm	0.00699	0.137	CbGdCrCtD
Dihydroxyaluminium—VDAC1—Isotretinoin—Alitretinoin—peripheral nervous system neoplasm	0.00699	0.137	CbGdCrCtD
Dihydroxyaluminium—Visual disturbance—Tretinoin—peripheral nervous system neoplasm	0.00658	0.0079	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Isotretinoin—peripheral nervous system neoplasm	0.00658	0.0079	CcSEcCtD
Dihydroxyaluminium—Extravasation—Cisplatin—peripheral nervous system neoplasm	0.00635	0.00763	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Melphalan—peripheral nervous system neoplasm	0.00618	0.00742	CcSEcCtD
Dihydroxyaluminium—Coma—Alitretinoin—peripheral nervous system neoplasm	0.00595	0.00714	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Dactinomycin—peripheral nervous system neoplasm	0.00591	0.0071	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Alitretinoin—peripheral nervous system neoplasm	0.00582	0.00699	CcSEcCtD
Dihydroxyaluminium—Extravasation—Etoposide—peripheral nervous system neoplasm	0.00582	0.00699	CcSEcCtD
Dihydroxyaluminium—Dehydration—Tretinoin—peripheral nervous system neoplasm	0.0058	0.00696	CcSEcCtD
Dihydroxyaluminium—Dehydration—Isotretinoin—peripheral nervous system neoplasm	0.0058	0.00696	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Etoposide—peripheral nervous system neoplasm	0.00578	0.00694	CcSEcCtD
Dihydroxyaluminium—Coma—Vincristine—peripheral nervous system neoplasm	0.00573	0.00688	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Alitretinoin—peripheral nervous system neoplasm	0.00548	0.00658	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Epirubicin—peripheral nervous system neoplasm	0.00527	0.00633	CcSEcCtD
Dihydroxyaluminium—Polyuria—Vincristine—peripheral nervous system neoplasm	0.00518	0.00622	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Alitretinoin—peripheral nervous system neoplasm	0.00498	0.00598	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—peripheral nervous system neoplasm	0.00488	0.00586	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Cisplatin—peripheral nervous system neoplasm	0.00467	0.00561	CcSEcCtD
Dihydroxyaluminium—Polyuria—Cisplatin—peripheral nervous system neoplasm	0.00458	0.0055	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Vincristine—peripheral nervous system neoplasm	0.00457	0.00549	CcSEcCtD
Dihydroxyaluminium—Dehydration—Alitretinoin—peripheral nervous system neoplasm	0.00439	0.00527	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Topotecan—peripheral nervous system neoplasm	0.00436	0.00523	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Vincristine—peripheral nervous system neoplasm	0.00433	0.0052	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Etoposide—peripheral nervous system neoplasm	0.00428	0.00514	CcSEcCtD
Dihydroxyaluminium—Dehydration—Vincristine—peripheral nervous system neoplasm	0.00423	0.00508	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Tretinoin—peripheral nervous system neoplasm	0.00415	0.00499	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Isotretinoin—peripheral nervous system neoplasm	0.00415	0.00499	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Cisplatin—peripheral nervous system neoplasm	0.00404	0.00485	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Epirubicin—peripheral nervous system neoplasm	0.00402	0.00483	CcSEcCtD
Dihydroxyaluminium—Chills—Topotecan—peripheral nervous system neoplasm	0.0039	0.00468	CcSEcCtD
Dihydroxyaluminium—Chills—Tretinoin—peripheral nervous system neoplasm	0.00387	0.00464	CcSEcCtD
Dihydroxyaluminium—Chills—Isotretinoin—peripheral nervous system neoplasm	0.00387	0.00464	CcSEcCtD
Dihydroxyaluminium—Dehydration—Cisplatin—peripheral nervous system neoplasm	0.00374	0.00449	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—peripheral nervous system neoplasm	0.00372	0.00447	CcSEcCtD
Dihydroxyaluminium—Back pain—Topotecan—peripheral nervous system neoplasm	0.00366	0.00439	CcSEcCtD
Dihydroxyaluminium—Back pain—Tretinoin—peripheral nervous system neoplasm	0.00363	0.00436	CcSEcCtD
Dihydroxyaluminium—Back pain—Isotretinoin—peripheral nervous system neoplasm	0.00363	0.00436	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Isotretinoin—peripheral nervous system neoplasm	0.00354	0.00425	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Tretinoin—peripheral nervous system neoplasm	0.00354	0.00425	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—peripheral nervous system neoplasm	0.00326	0.00392	CcSEcCtD
Dihydroxyaluminium—Convulsion—Tretinoin—peripheral nervous system neoplasm	0.00325	0.0039	CcSEcCtD
Dihydroxyaluminium—Convulsion—Isotretinoin—peripheral nervous system neoplasm	0.00325	0.0039	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—peripheral nervous system neoplasm	0.00324	0.00389	CcSEcCtD
Dihydroxyaluminium—Convulsion—Melphalan—peripheral nervous system neoplasm	0.00321	0.00385	CcSEcCtD
Dihydroxyaluminium—Chills—Dactinomycin—peripheral nervous system neoplasm	0.00316	0.0038	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Alitretinoin—peripheral nervous system neoplasm	0.00315	0.00378	CcSEcCtD
Dihydroxyaluminium—Infection—Topotecan—peripheral nervous system neoplasm	0.00307	0.00368	CcSEcCtD
Dihydroxyaluminium—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.00306	0.00368	CcSEcCtD
Dihydroxyaluminium—Oedema—Tretinoin—peripheral nervous system neoplasm	0.00306	0.00368	CcSEcCtD
Dihydroxyaluminium—Infection—Tretinoin—peripheral nervous system neoplasm	0.00304	0.00365	CcSEcCtD
Dihydroxyaluminium—Infection—Isotretinoin—peripheral nervous system neoplasm	0.00304	0.00365	CcSEcCtD
Dihydroxyaluminium—Oedema—Melphalan—peripheral nervous system neoplasm	0.00302	0.00363	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—peripheral nervous system neoplasm	0.00302	0.00362	CcSEcCtD
Dihydroxyaluminium—Infection—Melphalan—peripheral nervous system neoplasm	0.003	0.00361	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—peripheral nervous system neoplasm	0.003	0.0036	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00299	0.00359	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00299	0.00359	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00295	0.00354	CcSEcCtD
Dihydroxyaluminium—Chills—Alitretinoin—peripheral nervous system neoplasm	0.00293	0.00352	CcSEcCtD
Dihydroxyaluminium—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.00286	0.00344	CcSEcCtD
Dihydroxyaluminium—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.00286	0.00344	CcSEcCtD
Dihydroxyaluminium—Hypotension—Melphalan—peripheral nervous system neoplasm	0.00283	0.00339	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—peripheral nervous system neoplasm	0.00276	0.00332	CcSEcCtD
Dihydroxyaluminium—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.00275	0.0033	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Cisplatin—peripheral nervous system neoplasm	0.00268	0.00322	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Alitretinoin—peripheral nervous system neoplasm	0.00268	0.00322	CcSEcCtD
Dihydroxyaluminium—Back pain—Vincristine—peripheral nervous system neoplasm	0.00265	0.00318	CcSEcCtD
Dihydroxyaluminium—Pain—Topotecan—peripheral nervous system neoplasm	0.00264	0.00317	CcSEcCtD
Dihydroxyaluminium—Pain—Tretinoin—peripheral nervous system neoplasm	0.00262	0.00314	CcSEcCtD
Dihydroxyaluminium—Pain—Isotretinoin—peripheral nervous system neoplasm	0.00262	0.00314	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—peripheral nervous system neoplasm	0.0026	0.00312	CcSEcCtD
Dihydroxyaluminium—Pain—Melphalan—peripheral nervous system neoplasm	0.00259	0.0031	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—peripheral nervous system neoplasm	0.00256	0.00307	CcSEcCtD
Dihydroxyaluminium—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.0025	0.00301	CcSEcCtD
Dihydroxyaluminium—Infection—Dactinomycin—peripheral nervous system neoplasm	0.00249	0.00299	CcSEcCtD
Dihydroxyaluminium—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.00246	0.00296	CcSEcCtD
Dihydroxyaluminium—Vertigo—Vincristine—peripheral nervous system neoplasm	0.00246	0.00296	CcSEcCtD
Dihydroxyaluminium—Urticaria—Topotecan—peripheral nervous system neoplasm	0.00245	0.00295	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.00244	0.00293	CcSEcCtD
Dihydroxyaluminium—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00243	0.00292	CcSEcCtD
Dihydroxyaluminium—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00243	0.00292	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.00242	0.00291	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.00242	0.00291	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—peripheral nervous system neoplasm	0.00241	0.00289	CcSEcCtD
Dihydroxyaluminium—Urticaria—Melphalan—peripheral nervous system neoplasm	0.0024	0.00288	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—peripheral nervous system neoplasm	0.0024	0.00288	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—peripheral nervous system neoplasm	0.00239	0.00287	CcSEcCtD
Dihydroxyaluminium—Convulsion—Vincristine—peripheral nervous system neoplasm	0.00237	0.00285	CcSEcCtD
Dihydroxyaluminium—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00232	0.00279	CcSEcCtD
Dihydroxyaluminium—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00231	0.00277	CcSEcCtD
Dihydroxyaluminium—Chills—Etoposide—peripheral nervous system neoplasm	0.00229	0.00275	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.00228	0.00274	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.00227	0.00273	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00227	0.00272	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00226	0.00271	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00226	0.00271	CcSEcCtD
Dihydroxyaluminium—Oedema—Vincristine—peripheral nervous system neoplasm	0.00224	0.00269	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00223	0.00267	CcSEcCtD
Dihydroxyaluminium—Infection—Vincristine—peripheral nervous system neoplasm	0.00222	0.00267	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—peripheral nervous system neoplasm	0.00222	0.00266	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—peripheral nervous system neoplasm	0.00221	0.00265	CcSEcCtD
Dihydroxyaluminium—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00217	0.0026	CcSEcCtD
Dihydroxyaluminium—Back pain—Etoposide—peripheral nervous system neoplasm	0.00215	0.00258	CcSEcCtD
Dihydroxyaluminium—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00214	0.00257	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00211	0.00254	CcSEcCtD
Dihydroxyaluminium—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.0021	0.00252	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.0021	0.00252	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.0021	0.00252	CcSEcCtD
Dihydroxyaluminium—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00209	0.00251	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.00207	0.00249	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00207	0.00248	CcSEcCtD
Dihydroxyaluminium—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00204	0.00245	CcSEcCtD
Dihydroxyaluminium—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00203	0.00243	CcSEcCtD
Dihydroxyaluminium—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00203	0.00243	CcSEcCtD
Dihydroxyaluminium—Vertigo—Etoposide—peripheral nervous system neoplasm	0.00199	0.00239	CcSEcCtD
Dihydroxyaluminium—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00199	0.00238	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.00198	0.00238	CcSEcCtD
Dihydroxyaluminium—Oedema—Cisplatin—peripheral nervous system neoplasm	0.00198	0.00237	CcSEcCtD
Dihydroxyaluminium—Infection—Cisplatin—peripheral nervous system neoplasm	0.00196	0.00236	CcSEcCtD
Dihydroxyaluminium—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00196	0.00236	CcSEcCtD
Dihydroxyaluminium—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00195	0.00234	CcSEcCtD
Dihydroxyaluminium—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00195	0.00234	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.00193	0.00232	CcSEcCtD
Dihydroxyaluminium—Convulsion—Etoposide—peripheral nervous system neoplasm	0.00192	0.00231	CcSEcCtD
Dihydroxyaluminium—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00192	0.00231	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.00192	0.00231	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.00192	0.00231	CcSEcCtD
Dihydroxyaluminium—Pain—Vincristine—peripheral nervous system neoplasm	0.00191	0.0023	CcSEcCtD
Dihydroxyaluminium—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00185	0.00222	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00184	0.00221	CcSEcCtD
Dihydroxyaluminium—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00184	0.00221	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.00184	0.0022	CcSEcCtD
Dihydroxyaluminium—Nausea—Topotecan—peripheral nervous system neoplasm	0.00183	0.0022	CcSEcCtD
Dihydroxyaluminium—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00182	0.00218	CcSEcCtD
Dihydroxyaluminium—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00182	0.00218	CcSEcCtD
Dihydroxyaluminium—Infection—Etoposide—peripheral nervous system neoplasm	0.0018	0.00216	CcSEcCtD
Dihydroxyaluminium—Nausea—Melphalan—peripheral nervous system neoplasm	0.0018	0.00216	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.00178	0.00214	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00177	0.00212	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00177	0.00212	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.00174	0.00209	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00171	0.00206	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00171	0.00205	CcSEcCtD
Dihydroxyaluminium—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00169	0.00203	CcSEcCtD
Dihydroxyaluminium—Pain—Cisplatin—peripheral nervous system neoplasm	0.00169	0.00203	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00165	0.00198	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00161	0.00193	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00159	0.00191	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00159	0.00191	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00156	0.00188	CcSEcCtD
Dihydroxyaluminium—Pain—Etoposide—peripheral nervous system neoplasm	0.00155	0.00186	CcSEcCtD
Dihydroxyaluminium—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00154	0.00184	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00153	0.00184	CcSEcCtD
Dihydroxyaluminium—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00149	0.00179	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00148	0.00178	CcSEcCtD
Dihydroxyaluminium—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00148	0.00177	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00146	0.00175	CcSEcCtD
Dihydroxyaluminium—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00144	0.00173	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.00143	0.00172	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00143	0.00172	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00142	0.00171	CcSEcCtD
Dihydroxyaluminium—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00138	0.00166	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.00138	0.00165	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00135	0.00162	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00133	0.0016	CcSEcCtD
Dihydroxyaluminium—Nausea—Vincristine—peripheral nervous system neoplasm	0.00133	0.0016	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.00133	0.00159	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—peripheral nervous system neoplasm	0.00128	0.00154	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.00127	0.00153	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00126	0.00151	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00124	0.00149	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—peripheral nervous system neoplasm	0.0012	0.00145	CcSEcCtD
Dihydroxyaluminium—Dizziness—Etoposide—peripheral nervous system neoplasm	0.0012	0.00144	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00119	0.00143	CcSEcCtD
Dihydroxyaluminium—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00117	0.00141	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.00117	0.00141	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00115	0.00138	CcSEcCtD
Dihydroxyaluminium—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.00112	0.00134	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.00111	0.00134	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.00109	0.0013	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00108	0.00129	CcSEcCtD
Dihydroxyaluminium—Nausea—Etoposide—peripheral nervous system neoplasm	0.00108	0.00129	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.00103	0.00124	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00102	0.00122	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—peripheral nervous system neoplasm	0.00101	0.00121	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000998	0.0012	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000991	0.00119	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000949	0.00114	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.00094	0.00113	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000934	0.00112	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000917	0.0011	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000878	0.00105	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—peripheral nervous system neoplasm	0.000869	0.00104	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000807	0.000969	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000804	0.000965	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000803	0.000964	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000748	0.000898	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000747	0.000896	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000743	0.000892	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000695	0.000834	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000692	0.000831	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000672	0.000806	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000646	0.000775	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000643	0.000772	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000621	0.000746	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000603	0.000724	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000598	0.000717	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000558	0.00067	CcSEcCtD
